Talazoparib Clinical Trials
18 recruitingDrug
Phase 214Phase 17
Showing 1–18 of 18 trials
Recruiting
Phase 2
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Prostate Cancer Clinical Trials Consortium126 enrolled2 locationsNCT06844383
Recruiting
Phase 1
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
Acute Myeloid Leukemia
Norman J. Lacayo34 enrolled9 locationsNCT05101551
Recruiting
Phase 2
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmAdvanced Malignant Solid Neoplasm
National Cancer Institute (NCI)88 enrolled36 locationsNCT05327010
Recruiting
Phase 2
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+28 more
National Cancer Institute (NCI)36 enrolled4 locationsNCT04550494
Recruiting
Phase 1Phase 2
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRecurrent Solid Tumor+19 more
St. Jude Children's Research Hospital90 enrolled10 locationsNCT04901702
Recruiting
Phase 2
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Advanced Solid TumorsMultiple MyelomaLymphoma, Non-Hodgkin
American Society of Clinical Oncology4,200 enrolled174 locationsNCT02693535
Recruiting
Phase 1Phase 2
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Cancer
Alliance Foundation Trials, LLC.148 enrolled21 locationsNCT04486352
Recruiting
Phase 1
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
Malignant Female Reproductive System NeoplasmStage IV Cervical Cancer AJCC v8Stage IVA Cervical Cancer AJCC v8+22 more
M.D. Anderson Cancer Center24 enrolled2 locationsNCT03968406
Recruiting
Phase 2
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
Stage IV Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Metastatic Prostate Adenocarcinoma+2 more
City of Hope Medical Center70 enrolled1 locationNCT04734730
Recruiting
Phase 2
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
Prostate Cancer
M.D. Anderson Cancer Center30 enrolled1 locationNCT05873192
Recruiting
Phase 2
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Breast Cancer
Massachusetts General Hospital30 enrolled7 locationsNCT03990896
Recruiting
Phase 1Phase 2
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
Advanced Refractory Solid TumorsAdvanced Triple Negative Breast CancersMetastatic Triple Negative Breast Cancers
National University Hospital, Singapore63 enrolled1 locationNCT05035745
Recruiting
Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Alexander B Olawaiye, MD33 enrolled1 locationNCT05071937
Recruiting
Phase 2
FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test
Advanced Breast Cancer
Erasmus Medical Center66 enrolled3 locationsNCT06193525
Recruiting
Phase 1
PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours
Neuroendocrine Tumors
Peter MacCallum Cancer Centre, Australia24 enrolled1 locationNCT05053854
Recruiting
Phase 1
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Chronic Myelomonocytic LeukemiaPolycythemia VeraPrimary Myelofibrosis+3 more
Fox Chase Cancer Center24 enrolled1 locationNCT06218628
Recruiting
Phase 2
The Drug Rediscovery Protocol (DRUP Trial)
CancerNeoplasmNeoplasia+1 more
The Netherlands Cancer Institute1,550 enrolled36 locationsNCT02925234
Recruiting
Phase 2
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Oslo University Hospital40 enrolled1 locationNCT05725200